Page last updated: 2024-08-25

bexarotene and Mycosis Fungoides

bexarotene has been researched along with Mycosis Fungoides in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	39 (43.33)	29.6817
2010's	35 (38.89)	24.3611
2020's	16 (17.78)	2.80

Authors

Authors	Studies
Ahmadu, C; Armstrong, N; Chalker, A; Duffy, S; Grimm, SE; Hiligsmann, M; Joore, MA; Kleijnen, J; Ryder, S; Syndikus, I; Wijnen, B; Witlox, W; Wolff, R	1
Eich, HT; Elsayad, K; Livingstone, E; Moritz, RKC; Müller, EC; Nawar, T; Rolf, D; Stadler, R; Steinbrink, K; Stranzenbach, R; Sunderkötter, C; Weishaupt, C	1
Demirci Saadet, E; Kalay Yildizhan, I; Okcu Heper, A; Sanli, H	1
Bayramgürler, D; Demirbaş, A; Demirkesen, C; Eruyar, T; Kazan, D	1
Ginsburg, E; Hennessy, K; Mhaskar, R; Seminario-Vidal, L	1
Asano, Y; Fujimura, T; Hashimoto, A; Kambayashi, Y; Tamabuchi, E; Yamamoto, H	1
Ardigò, M; Cicini, MP; Franceschini, C; Mandel, VD; Saraceni, PL; Teoli, M	1
Christensen, LF; Cooper, KD; Ellis, A; Kord, H; Meyerson, H; Sharma, T	1
Bunch, C; Jäger, M; Schmitt, J; Valipour, A; Weberschock, T; Wu, P	1
Briones, J; Espeso, M; Martín, A; Mozos, A; Novelli, S; Sánchez, JJ	1
Hisamoto, T; Kawana, Y; Miyagaki, T; Oka, T; Sato, S; Suga, H; Sugaya, M	1
Foss, F; Montanari, F; Reddy, N; Sethi, TK	1
Zic, JA	1
Gulekon, A; Tamer, F	1
Alpdogan, SO; Cha, J; Correia, E; Krishnasamy, S; Nikbakht, N; O'Donnell, M; Porcu, P; Sahu, J; Shi, W; Zaya, R	1
Einar French, L; Guertler, A; Helene Frommherz, L; Kaemmerer, T; Reinholz, M; Stadler, PC	1
Duvic, M; Huang, S; Lewis, DJ	1
Assaf, C; Nicolay, JP	1
Astrua, C; Fava, P; Fuligni, F; Grandi, V; Guglielmo, A; Gunnella, S; Patrizi, A; Pileri, A; Pimpinelli, N; Quaglino, P; Simontacchi, G	1
Hamada, T; Iwatsuki, K; Kawai, K; Kiyohara, E; Matsushita, S; Nagatani, T; Ohtsuka, M; Saida, T; Setoyama, M; Sugaya, M; Tani, M; Tokura, Y; Tsuboi, R; Yonekura, K	1
Alfano, R; Argenziano, G; Caccavale, S; Franco, R; Jurakic Toncic, R; Panarese, I; Ronchi, A; Sica, A; Vitiello, P	1
Duvic, M; Park, KE; Ramachandran, V	1
Calderon Cabrera, C; Carrillo Cruz, E; de la Cruz Vicente, F; Espigado Tocino, I; Falantes, JF; Marín-Niebla, A; Martino Galiana, ML; Perez-Simón, JA; Prats Martín, C; Rios Herranz, E	1
Cowper, S; Girardi, M; Huang, J; Moss, J	1
Deonizio, JM; Guitart, J; Vaghani, SP	1
Atmaca, H; Islek, I; Sentürk, N	1
Duvic, M; Gangar, P; Talpur, R; Thompson, A	1
Dalle, S; Graeppi-Dulac, J; Orgiazzi, J; Perier-Muzet, M; Vlaeminck-Guillem, V	1
Helbig, D; Wirtz, M	1
Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S	1
Fabri, M; Felcht, M; Herling, M; Klemke, CD; Mrotzek, C; Schlaak, M; Schrader, A; Sommer, A	1
Acebo-Mariñas, E; Aperribay-Esparza, A; de Quintana-Sancho, A; Gardeazabal-García, J	1
Huen, AO; Kim, EJ	1
Chiacchio, R; Errichetti, E; Piccirillo, A	1
Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S	1
Broussard, KC; Patrawala, SA; Wang, L; Zic, JA	1
Bagot, M; Bouaziz, JD; Haber, R; Jachiet, M; Laly, P; Ram-Wolff, C; Rivet, J	1
Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A	1
Acebo, E; Díaz-Pérez, JL; García-Ruiz, JC; Izu, R; Martínez de Lagrán, Z; Pérez-Barrio, S	1
Bertsch, HP; Kaune, KM; Klemke, CD; Krüger, U; Mitteldorf, C; Neumann, C	1
Fleischer, AB; Kannangara, AP; Levitan, D	1
Abbott, RA; Bashir, SJ; Hung, T; Morris, SL; Russell-Jones, R; Scarisbrick, JJ; Whittaker, SJ	1
Tronnier, M	1
D'Acunto, C; Gurioli, C; Neri, I	1
Amitay-Laish, I; David, M; Hodak, E	1
Climent, J; Estrach, T; Gallardo, F; Garcia-Muret, P; Muniesa, C; Pujol, RM; Servitje, O	1
Farley-Loftus, R; Latkowski, JA; Mandal, R	1
Baron, E; Bohjanen, K; Demierre, MF; Duvic, M; Eubank, K; Geskin, L; Miller, DR; Pugliese, S; Talpur, R; Tharp, M; Zic, JA	1
Cutlan, J; Duvic, M; Holcomb, M	1
Altiner, A; Berger, E; Chu, J; Latkowski, JA; Patel, R; Sanders, S	1
Baykal, C; Buyukbabani, N; Topkarci, Z; Yazganoglu, KD	1
Andea, A; Hughey, LC; Stewart, FA	1
Schmidt, C	1
Hall, AG; Marshall, GD; Morris, AE	1
Cheeley, J; DeLong, LK; Parker, SR; Sahn, RE	1
Ahmed, Z; Piguet, V	1
Dummer, R; Gellrich, S; Hasan, B; Karrasch, M; Knobler, R; Meulemans, B; Ortiz, P; Ranki, A; Stadler, R; Whittaker, S	1
Assaf, C; Becker, JC; Dummer, R; Duvic, M; Grazia Bernengo, M; Lebbé, C; Marshood, M; Ortiz Romero, P; Poulalhon, N; Prince, HM; Squier, M; Tai, F; Williams, D	1
Keun, YK; Sangueza, O; Woodruff, R	1
Apisarnthanarax, N; Breuer-Mcham, J; Duvic, M; Talpur, R; Ward, S	1
Duvic, M; Lain, T; Talpur, R	1
Apisarnthanarax, N; Duvic, M; Ha, CS	1
Lebwohl, M; Stern, DK	1
Duvic, M; Hanson, M; Hill, A	1
Crawford, G; Junkins-Hopkins, JM; McGinnis, KS; Rook, AH; Shapiro, M; Vittorio, CC	1
Huber, MA; Kunzi-Rapp, K; Scharffetter-Kochanek, K; Staib, G	1
Mehlmauer, MA	1
Burg, G; Cozzio, A; Dummer, R; Graf, P; Kempf, W; Michaelis, S	1
Andreeff, M; Duvic, M; Konopleva, M; Ni, X; Zhang, C	1
Foss, F	1
Bouwhuis, SA; Davis, MD; el-Azhary, RA; Gibson, LE; Kist, JM; Knudsen, JM; McEvoy, MT; Pittelkow, MR	1
Coors, EA; Von den Driesch, P	1
Duvic, M; Talpur, R	1
Burg, G; Dummer, R; Hauschild, A; Skalsky, J; Weichenthal, M	1
Arrue, I; Fernández-Herrera, J; García-Romero, D; Ortiz-Romero, PL; Polo, I; Rosales, B; Ruiz, D; Sánchez-Largo, ME; Sanz, H; Valverde, R; Vanaclocha, F	1
García-Arpa, M; González-García, J; Rodríguez-Vázquez, M	1
Bradley, B; Parker, SR	1
Bertsch, HP; Mitteldorf, C; Neumann, C; Stadler, R	1
Dervenoulas, J; Economopoulos, T; Giannopoulou, V; Girkas, K; Kaitsa, I; Kapsimali, V; Papageorgiou, E; Papageorgiou, S; Pappa, V; Stavrianeas, N; Tsirigotis, P	1
Scheinfeld, N	1
Lokitz, ML; Wong, HK	1
Alegre de Miquel, V; Pérez Ferriols, A; Roche Gamón, E; Vilata Corell, JJ	1
Gerami, P; Scupham, RK; Swick, BL; Walling, HW	1
Bachelez, H	1
Coors, E	1
Dalle, S; Thomas, L	1
Otremba, B	1
Stein, A	1
Antoniou, C; Katsambas, A; Nikolaou, V; Papadavid, E; Siakantaris, M; Stavrianeas, N; Stratigos, A; Vassilakopoulos, TP	1
Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W	1

Reviews

16 review(s) available for bexarotene and Mycosis Fungoides

Article	Year
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 2022, Volume: 40, Issue:5 Topics: Adult; Antibodies, Monoclonal, Humanized; Bexarotene; Cost-Benefit Analysis; Humans; Mycosis Fungoides; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sezary Syndrome; Skin Neoplasms; State Medicine; Technology; Technology Assessment, Biomedical; Vorinostat	2022
Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis. Dermatologic therapy, 2022, Volume: 35, Issue:5 Topics: Adult; Bexarotene; Female; Humans; Male; Mycosis Fungoides; Phototherapy; Prospective Studies; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2022
Interventions for mycosis fungoides. The Cochrane database of systematic reviews, 2020, 07-07, Volume: 7 Topics: Acitretin; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Humans; Immunologic Factors; Interferon-alpha; Mycosis Fungoides; Neoplasm Staging; Photochemotherapy; Photopheresis; PUVA Therapy; Randomized Controlled Trials as Topic; Skin Neoplasms	2020
How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome. British journal of haematology, 2021, Volume: 195, Issue:3 Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Electrons; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Interferon-alpha; Male; Mycosis Fungoides; Neoplasm Staging; Neoplastic Stem Cells; Photopheresis; Prognosis; PUVA Therapy; Retinoids; Sezary Syndrome; Signal Transduction; Skin Neoplasms; T-Lymphocyte Subsets	2021
Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma. The Medical clinics of North America, 2021, Volume: 105, Issue:4 Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arthropods; Bexarotene; Bites and Stings; Brentuximab Vedotin; Diagnosis, Differential; Humans; Hyperlipidemias; Hypothyroidism; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Mycosis Fungoides; Peripheral Nervous System Diseases; Prognosis; Sezary Syndrome; Skin Diseases; Skin Neoplasms	2021
[Treatment of mycosis fungoides and Sézary syndrome]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2017, Volume: 68, Issue:9 Topics: Adrenal Cortex Hormones; Bexarotene; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immunoconjugates; Interferon-alpha; Mycosis Fungoides; Neoplasm Recurrence, Local; Neoplasm Staging; Phototherapy; Polyethylene Glycols; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; World Health Organization	2017
Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. European journal of endocrinology, 2014, Volume: 170, Issue:6 Topics: Aged; Antineoplastic Agents; Bexarotene; Endocrine System Diseases; Female; Gene Expression; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Thyroid Gland; Thyrotropin; Thyrotropin, beta Subunit	2014
Systematic review of combination therapies for mycosis fungoides. Cancer treatment reviews, 2014, Volume: 40, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine; Ficusin; Gemcitabine; Humans; Hydroxamic Acids; Interferon-alpha; Methotrexate; Mycosis Fungoides; Phototherapy; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat	2014
The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatologic clinics, 2015, Volume: 33, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Humans; Hyperlipidemias; Hypothyroidism; Immunologic Factors; Interferons; Mycosis Fungoides; PUVA Therapy; Retinoids; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2015
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. American journal of hematology, 2008, Volume: 83, Issue:9 Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2008
Mycosis fungoides stage IB progressing to cutaneous tumors. Dermatology online journal, 2011, Oct-15, Volume: 17, Issue:10 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Black or African American; Disease Progression; Female; Humans; Interferon-alpha; Methotrexate; Mycosis Fungoides; Skin Neoplasms; Skin Pigmentation; Tetrahydronaphthalenes; Ultraviolet Therapy	2011
Not all that itches is urticaria. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 109, Issue:1 Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Bexarotene; Biopsy, Needle; Black or African American; Diagnosis, Differential; Education, Medical, Continuing; Eosinophilia; Female; Humans; Ki-1 Antigen; Methotrexate; Middle Aged; Mycosis Fungoides; Prednisone; Pruritus; Skin Neoplasms; Tetrahydronaphthalenes; Urticaria	2012
Mycosis fungoides and the Sézary syndrome. Current opinion in oncology, 2004, Volume: 16, Issue:5 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Mycosis Fungoides; Neoplasm Staging; Prognosis; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2004
Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A. The British journal of dermatology, 2005, Volume: 152, Issue:6 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Male; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2005
Treatment of cutaneous T-cell lymphoma/mycosis fungoides. Dermatology nursing, 2006, Volume: 18, Issue:6 Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antineoplastic Agents; Bexarotene; Biopsy; Cost of Illness; Diphtheria Toxin; Foundations; Humans; Hydroxamic Acids; Interferons; Interleukin-2; Mechlorethamine; Mycosis Fungoides; Neoplasm Staging; Photopheresis; Phototherapy; Physical Examination; Radiotherapy; Recombinant Fusion Proteins; Retinoids; Self-Help Groups; Skin Care; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat	2006
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. Journal of drugs in dermatology : JDD, 2007, Volume: 6, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bexarotene; Diphtheria Toxin; Drug Approval; Humans; Hydroxamic Acids; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat	2007

Trials

5 trial(s) available for bexarotene and Mycosis Fungoides

Article	Year
Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201). The Journal of dermatology, 2019, Volume: 46, Issue:7 Topics: Adult; Antineoplastic Agents; Bexarotene; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Japan; Leukopenia; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Male; Mycosis Fungoides; Neoplasm Staging; Neutropenia; Skin Neoplasms; Time Factors; Young Adult	2019
Multicenter photopheresis intervention trial in early-stage mycosis fungoides. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bexarotene; CD4 Lymphocyte Count; Female; Humans; Interferon-alpha; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Photopheresis; Quality of Life; T-Lymphocytes; Tetrahydronaphthalenes; Treatment Outcome	2011
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056 The British journal of dermatology, 2012, Volume: 167, Issue:3 Topics: Adolescent; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Early Termination of Clinical Trials; Humans; Infant; Methoxsalen; Middle Aged; Mycosis Fungoides; Photosensitizing Agents; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Young Adult	2012
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Disease Progression; Disease-Free Survival; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Mycosis Fungoides; Panobinostat; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2013
Long-term control of mycosis fungoides of the hands with topical bexarotene. International journal of dermatology, 2003, Volume: 42, Issue:3 Topics: Administration, Topical; Adult; Anticarcinogenic Agents; Bexarotene; Hand; Humans; Male; Mycosis Fungoides; Skin; Skin Neoplasms; Tetrahydronaphthalenes	2003

Other Studies

69 other study(ies) available for bexarotene and Mycosis Fungoides

Article	Year
Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022, Volume: 20, Issue:3 Topics: Bexarotene; Electrons; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome	2022
Complete remission with bexarotene gel in unilesional folliculotropic mycosis fungoides located on the scalp. Dermatologic therapy, 2022, Volume: 35, Issue:4 Topics: Bexarotene; Humans; Mycosis Fungoides; Remission Induction; Scalp; Skin Neoplasms	2022
The oral cavity and gastric involvement in mycosis fungoides while on systemic bexarotene therapy: A rare case report. Dermatologic therapy, 2022, Volume: 35, Issue:4 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Mouth; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2022
Successful treatment of CD8+ syringotropic mycosis fungoides with bexarotene and local radiotherapy. Dermatologic therapy, 2022, Volume: 35, Issue:11 Topics: Bexarotene; CD8-Positive T-Lymphocytes; Humans; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2022
Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:21 Topics: Adult; Bexarotene; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms	2022
CD30 Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:2 Topics: Aged; Bexarotene; Humans; Ki-1 Antigen; Male; Middle Aged; Mycosis Fungoides; Photopheresis; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes; Treatment Outcome; Vorinostat	2021
Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units. European journal of dermatology : EJD, 2020, Aug-01, Volume: 30, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Palliative Care; Prednisone; Referral and Consultation; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Spain; Survival Analysis; Transplantation, Homologous; Vincristine	2020
A case of mycosis fungoides successfully treated with combination of bexarotene and mogamulizumab. Dermatologic therapy, 2021, Volume: 34, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Bexarotene; Humans; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2021
Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2021, Volume: 30, Issue:6 Topics: Anticarcinogenic Agents; Bexarotene; Biomarkers; Humans; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2021
Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study. Journal of the American Academy of Dermatology, 2022, Volume: 86, Issue:6 Topics: Bexarotene; Brentuximab Vedotin; Cell Transformation, Neoplastic; Humans; Mycosis Fungoides; Prognosis; Retrospective Studies; Skin Neoplasms	2022
Alitretinoin in the treatment of cutaneous T-cell lymphoma. Cancer medicine, 2021, Volume: 10, Issue:20 Topics: Adult; Aged; Alitretinoin; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Sezary Syndrome; Skin Neoplasms	2021
Oral bexarotene for post-transplant cutaneous T-cell lymphoma. Dermatologic therapy, 2017, Volume: 30, Issue:5 Topics: Administration, Oral; Anticarcinogenic Agents; Bexarotene; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Treatment Outcome	2017
Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:10 Topics: Bexarotene; Doxorubicin; Humans; Liposomes; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Pilot Projects	2019
Dermoscopic characterization of folliculotropic mycosis fungoides selectively localized on trunk and limbs. International journal of dermatology, 2019, Volume: 58, Issue:10 Topics: Bexarotene; Biopsy; Dermoscopy; Diagnosis, Differential; Extremities; Humans; Lymphoma; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin; Skin Neoplasms; Torso; Treatment Outcome	2019
Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later. International journal of dermatology, 2019, Volume: 58, Issue:11 Topics: Administration, Cutaneous; Adult; Antineoplastic Agents; Bexarotene; Hand; Humans; Male; Mycosis Fungoides; Skin Neoplasms; Time Factors; Treatment Outcome	2019
Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome. British journal of haematology, 2013, Volume: 162, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cyclophosphamide; Humans; Mycosis Fungoides; Pentostatin; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2013
Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal of drugs in dermatology : JDD, 2013, Volume: 12, Issue:4 Topics: Administration, Oral; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Ficusin; Follow-Up Studies; Humans; Lasers, Excimer; Male; Middle Aged; Mycosis Fungoides; Photosensitizing Agents; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2013
Topical bexarotene for psoralen plus ultraviolet A-induced photodamage. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:2 Topics: Administration, Topical; Bexarotene; Follow-Up Studies; Humans; Male; Middle Aged; Mycosis Fungoides; Photosensitivity Disorders; PUVA Therapy; Risk Assessment; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2013
Reversible pituitary insufficiency due to bexarotene therapy in a patient with mycosis fungoides. Pituitary, 2014, Volume: 17, Issue:5 Topics: Adrenal Insufficiency; Anticarcinogenic Agents; Bexarotene; Humans; Hypertriglyceridemia; Hypogonadism; Hypopituitarism; Hypothyroidism; Male; Middle Aged; Mycosis Fungoides; Tetrahydronaphthalenes	2014
Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Neoplasm Recurrence, Local; Retrospective Studies; Tetrahydronaphthalenes; Treatment Outcome	2014
[Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2014, Volume: 65, Issue:4 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Hodgkin Disease; Humans; Male; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2014
Vitamin D controls apoptosis and proliferation of cutaneous T-cell lymphoma cells. Experimental dermatology, 2015, Volume: 24, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Bexarotene; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Mycosis Fungoides; Receptors, Calcitriol; Retinoid X Receptors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Vitamin D; Vitamin D Deficiency	2015
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:8 Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Memory Disorders; Methotrexate; Middle Aged; Mycosis Fungoides; Nystagmus, Pathologic; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2015
Folliculotropic mycosis fungoides presenting as non-inflammatory scarring scalp alopecia associated with comedo-like lesions. International journal of dermatology, 2016, Volume: 55, Issue:1 Topics: Alopecia; Bexarotene; Biopsy, Needle; Cicatrix; Diagnosis, Differential; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Mycosis Fungoides; Risk Assessment; Scalp Dermatoses; Severity of Illness Index; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2016
[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]. Medicina clinica, 2016, Feb-05, Volume: 146, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cholesterol, HDL; Combined Modality Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Salvage Therapy; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine	2016
Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome. Dermatology online journal, 2016, May-15, Volume: 22, Issue:5 Topics: Age Factors; Aged; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Cell Transformation, Neoplastic; Disease Progression; Female; Furocoumarins; Humans; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Prognosis; Radiotherapy; Retrospective Studies; Skin; Skin Neoplasms; Tertiary Care Centers; Tetrahydronaphthalenes; Ultraviolet Therapy	2016
Photo-sensitive mycosis fungoides: a new variant? European journal of dermatology : EJD, 2017, 04-01, Volume: 27, Issue:2 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Depsipeptides; Humans; Male; Middle Aged; Mycosis Fungoides; Photosensitivity Disorders; Skin Neoplasms; Tetrahydronaphthalenes	2017
[Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides]. Actas dermo-sifiliograficas, 2008, Volume: 99, Issue:7 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Mechlorethamine; Methylprednisolone; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Prednisone; PUVA Therapy; Recombinant Proteins; Remission Induction; Tetrahydronaphthalenes; Transplantation, Autologous; Vincristine	2008
Bexarotene does not prevent secondary Hodgkin's lymphoma in mycosis fungoides. Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:5 Topics: Anticarcinogenic Agents; Bexarotene; Female; Hodgkin Disease; Humans; Immunophenotyping; Middle Aged; Mycosis Fungoides; Tetrahydronaphthalenes	2009
Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. The Journal of dermatological treatment, 2009, Volume: 20, Issue:3 Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Retrospective Studies; Risk Assessment; Sex Factors; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome	2009
Bexarotene therapy for mycosis fungoides and Sézary syndrome. The British journal of dermatology, 2009, Volume: 160, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Cohort Studies; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Retrospective Studies; Sex Factors; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2009
Foreign-body-associated granulomatous slack skin in folliculotropic mycosis fungoides of childhood. Journal of cutaneous pathology, 2009, Volume: 36, Issue:5 Topics: Adolescent; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Foreign Bodies; Giant Cells; Humans; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Male; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2009
Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB. The Journal of dermatological treatment, 2010, Volume: 21, Issue:1 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Female; Humans; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2010
Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides. Journal of the American Academy of Dermatology, 2009, Volume: 61, Issue:2 Topics: Bexarotene; Biopsy, Needle; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Mycosis Fungoides; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retreatment; Risk Assessment; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2009
Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. Journal of the American Academy of Dermatology, 2010, Volume: 62, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bexarotene; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2010
Poikilodermatous mycosis fungoides. Dermatology online journal, 2010, Nov-15, Volume: 16, Issue:11 Topics: Acitretin; Antineoplastic Agents; Bexarotene; Female; Humans; Hydroxamic Acids; Hypopigmentation; Immunophenotyping; Interferon-alpha; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Ultraviolet Therapy; Vorinostat	2010
Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides. International journal of dermatology, 2012, Volume: 51, Issue:10 Topics: Aged; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Electrons; Erythema; Humans; Male; Mechlorethamine; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Triamcinolone	2012
Childhood mycosis fungoides: a report of 20 cases from Turkey. Journal of the European Academy of Dermatology and Venereology : JEADV, 2013, Volume: 27, Issue:3 Topics: Adolescent; Adrenal Cortex Hormones; Bexarotene; Carmustine; Child; Child, Preschool; Humans; Mycosis Fungoides; Photochemotherapy; Tetrahydronaphthalenes; Turkey	2013
Mycosis fungoides-associated follicular mucinosis after bone-marrow transplantation. Journal of the American Academy of Dermatology, 2012, Volume: 66, Issue:6 Topics: Adult; Anticarcinogenic Agents; Bexarotene; Bone Marrow Transplantation; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Mucinosis, Follicular; Mycosis Fungoides; Tetrahydronaphthalenes	2012
Cutaneous T-cell lymphoma's confounding nature. Journal of the National Cancer Institute, 2012, Jun-06, Volume: 104, Issue:11 Topics: Aged; Alemtuzumab; Aminopterin; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brentuximab Vedotin; Delayed Diagnosis; Diagnosis, Differential; Humans; Immunoconjugates; Lymphoma, T-Cell, Cutaneous; Male; Mycosis Fungoides; Remission Induction; Sezary Syndrome; Stem Cell Transplantation; Tetrahydronaphthalenes; Transplantation, Homologous	2012
Acitretin for the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2013, Volume: 68, Issue:2 Topics: Acitretin; Adult; Aged; Aged, 80 and over; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2013
Combining rexinoids with psoralen-ultraviolet A sheds light on the management of mycosis fungoides. The British journal of dermatology, 2012, Volume: 167, Issue:3 Topics: Anticarcinogenic Agents; Bexarotene; Humans; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2012
Response of CD30+ large cell lymphoma of skin to bexarotene. Leukemia & lymphoma, 2002, Volume: 43, Issue:5 Topics: Aged; Aged, 80 and over; Bexarotene; Female; Humans; Ki-1 Antigen; Lymphoma, Large B-Cell, Diffuse; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2002
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:5 Topics: Algorithms; Anticarcinogenic Agents; Bexarotene; Dermatitis, Exfoliative; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypothyroidism; Middle Aged; Mycosis Fungoides; Photopheresis; Prospective Studies; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2002
Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy. American journal of clinical dermatology, 2003, Volume: 4, Issue:6 Topics: Administration, Oral; Adult; Anticarcinogenic Agents; Bexarotene; Cell Transformation, Neoplastic; Chemotherapy, Adjuvant; Female; Humans; Mucinosis, Follicular; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2003
Treatment of mycosis fungoides with oral bexarotene combined with PUVA. Journal of drugs in dermatology : JDD, 2002, Volume: 1, Issue:2 Topics: Anticarcinogenic Agents; Bexarotene; Female; Humans; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome	2002
Bexarotene reverses alopecia in cutaneous T-cell lymphoma. The British journal of dermatology, 2003, Volume: 149, Issue:1 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Bexarotene; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2003
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Drug Synergism; Drug Therapy, Combination; Humans; Interferon-alpha; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2004
Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:3 Topics: Administration, Oral; Aged; Anticarcinogenic Agents; Bexarotene; Drug Therapy, Combination; Ficusin; Humans; Male; Mycosis Fungoides; Tetrahydronaphthalenes; Ultraviolet Therapy	2004
Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene. Cutis, 2004, Volume: 73, Issue:6 Topics: Administration, Oral; Aged; Anticarcinogenic Agents; Bexarotene; Humans; Male; Mycosis Fungoides; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes	2004
Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides. Dermatology (Basel, Switzerland), 2004, Volume: 209, Issue:1 Topics: Anticarcinogenic Agents; Bexarotene; Drug Therapy, Combination; Female; Humans; Middle Aged; Mycosis Fungoides; PUVA Therapy; Tetrahydronaphthalenes	2004
The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. The Journal of investigative dermatology, 2004, Volume: 123, Issue:2 Topics: Anticarcinogenic Agents; Apoptosis; Bexarotene; Cell Division; Cell Line, Tumor; Drug Synergism; Humans; Immunologic Factors; Ligands; Lymphocytes; Mycosis Fungoides; Nitric Oxide; Oleanolic Acid; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Transcription Factors	2004
Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes	2005
Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. Clinical lymphoma & myeloma, 2006, Volume: 6, Issue:6 Topics: Administration, Oral; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Diphtheria Toxin; Female; Humans; Interleukin-2; Middle Aged; Mycosis Fungoides; PUVA Therapy; Recombinant Fusion Proteins; Tetrahydronaphthalenes; Treatment Outcome	2006
Bexarotene and systemic disease progression in CTCL? Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:2 Topics: Antineoplastic Agents; Bexarotene; Disease Progression; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Reproducibility of Results; Risk Factors; Sezary Syndrome; Tetrahydronaphthalenes	2006
[Treatment of mycosis fungoides with PUVA and bexarotene]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:5 Topics: Adult; Aged; Bexarotene; Female; Humans; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2006
Juvenile mycosis fungoides treated with bexarotene and PUVA. International journal of dermatology, 2007, Volume: 46, Issue:1 Topics: Adolescent; Anticarcinogenic Agents; Bexarotene; Biopsy; Humans; Male; Mycosis Fungoides; Neoplasm Staging; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2007
Folliculotropic mycosis fungoides with CD30+ large-cell transformation in a young woman: beneficial effect of bexarotene. The British journal of dermatology, 2007, Volume: 156, Issue:3 Topics: Adolescent; Antineoplastic Agents; Bexarotene; Female; Follow-Up Studies; Humans; Lymphoma, Large-Cell, Anaplastic; Mycosis Fungoides; Skin Neoplasms; Tetrahydronaphthalenes	2007
Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome. The British journal of dermatology, 2007, Volume: 156, Issue:6 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Photopheresis; Sezary Syndrome; Tetrahydronaphthalenes	2007
Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides. Photodermatology, photoimmunology & photomedicine, 2007, Volume: 23, Issue:6 Topics: Aged, 80 and over; Bexarotene; Humans; Male; Mycosis Fungoides; Tetrahydronaphthalenes; Ultraviolet Therapy	2007
[Mycosis fungoid treated with oral bexarotene: study of 13 cases]. Medicina clinica, 2007, Nov-10, Volume: 129, Issue:17 Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Disease Progression; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Tetrahydronaphthalenes; Time Factors; Treatment Outcome	2007
Folliculotropic mycosis fungoides responding to bexarotene gel. Journal of drugs in dermatology : JDD, 2008, Volume: 7, Issue:2 Topics: Aged; Anticarcinogenic Agents; Bexarotene; Gels; Humans; Male; Mycosis Fungoides; Tetrahydronaphthalenes; Treatment Outcome	2008
Bexarotene monotherapy for patients with advanced stage mycosis fungoides. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antineoplastic Agents; Bexarotene; Female; Humans; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antineoplastic Agents; Bexarotene; Combined Modality Therapy; Female; Humans; Mycosis Fungoides; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Humans; Interferons; Male; Methotrexate; Mycosis Fungoides; PUVA Therapy; Salvage Therapy; Skin Neoplasms; Tetrahydronaphthalenes	2008
Treatment of refractory stage IV mycosis fungoides with bexarotene monotherapy. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Adult; Antineoplastic Agents; Bexarotene; Humans; Male; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Tetrahydronaphthalenes	2008
Bexarotene monotherapy for patients with refractory early stage mycosis fungoides. Dermatologic clinics, 2008, Volume: 26 Suppl 1 Topics: Aged, 80 and over; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Mycosis Fungoides; Neoplasm Staging; Skin Neoplasms; Stroke; Tetrahydronaphthalenes	2008
Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. American journal of clinical dermatology, 2008, Volume: 9, Issue:3 Topics: Adult; Aged; Anticarcinogenic Agents; Bexarotene; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mycosis Fungoides; PUVA Therapy; Tetrahydronaphthalenes; Treatment Outcome	2008
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:5 Suppl 1 Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fever; Granuloma; Humans; Hydroxamic Acids; Hypolipidemic Agents; Middle Aged; Mycosis Fungoides; Necrosis; Remission Induction; Skin; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat	2008